Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial

REFERENCES

• Uchino S, Kellum JA, Bellomo R, Beginning and ending supportive therapy for the kidney (BEST kidney) investigators. Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA. 2005;294:813–818.
   PubMed Web of Science ®Google Scholar
• D'Intini V, Ronco C, Bonello M, Bellomo R. Renal replacement therapy in acute renal failure. Best Pract Res Clin Anaesthesiol. 2004;18:145–157.
   Google Scholar
• Hanson G, Moist L. Acute renal failure in the ICU. Assessing the utility of continuous renal replacement. J Crit Care. 2003;18:48–51.
   Google Scholar
• Oudemans-van Straaten HM, Wester JP, De Pont AC, Schetz MR. Anticoagulation strategies in continuous renal replacement therapy: Can the choice be evidence based? Intensive Care Med. 2006;134:188–202.
   Google Scholar
• Ricci Z, Ronco C, D'Amico G, Practice patterns in the management of acute renal failure in the critically ill patient: An international survey. Nephrol Dial Transplant. 2006;21:690–696.
   PubMed Web of Science ®Google Scholar
• Hetzel G, Sucker C. The heparins: All a nephrologist should know. Nephrol Dial Transplant. 2005;20:2036–2042.
   PubMed Web of Science ®Google Scholar
• Saltissi D, Morgan C, Westhuyzen J, Haely H. Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for hemodialysis anticoagulation. Nephrol Dial Transplant. 1999;14:2698–2703.
   PubMed Web of Science ®Google Scholar
• Wynckel A, Bernieh B, Toupance O, Guidelines to the use of enoxaparin in slow continuous hemodialysis. Contrib Nephrol. 1991;93:221–224.
   Google Scholar
• Sanderink G, Guimart C, Ozoux M, Jariwala N, Shukla U, Boutouyrie B. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res. 2002;105:225–231.
   PubMed Web of Science ®Google Scholar
• Farooq V, Hegarty J, Chandrasekar T, Serious adverse incidents with the usage of low-molecular-weight heparins in patients with chronic kidney disease. Am J Kidney Dis. 2004;43:531–537.
   PubMed Web of Science ®Google Scholar
• Aguilar D, Goldhaber S. Clinical uses of low-molecular weight heparin. Chest. 1999;115:1418–1423.
   Google Scholar
• Crowther MA, Berry LR, Monagle PT, Chan AK. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol. 2002;116:178–186.
   PubMed Web of Science ®Google Scholar
• Sagedal S, Hartmann A. Low-molecular-weight heparins as thromboprophylaxis in patients undergoing hemodialysis/hemofiltration or continuous renal replacement therapy. Eur J Med Res. 2004;9:125–130.
   Google Scholar
• Kruse MW, Lee JJ. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J. 2004;148:582–589.
   PubMed Web of Science ®Google Scholar
• Hirsh J, Warkentin TE, Shaughnessy S, Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119:64S–95S.
   PubMed Web of Science ®Google Scholar
• Heparin & LMWH. In: Hemostasis Brochura. Catalogo 27865: France: Diagnostica Stago; 1999.
   Google Scholar
• Miller R, Kingswood C, Bullen C, Cohen S. Renal replacement therapy in the ICU: The role of continuous arteriovenous hemodialysis. Br J Hosp Med. 1990;43:354–362.
   Google Scholar
• Davenport A. Anticoagulation for continuous renal replacement therapy. Contrib Nephrol. 2004;144:228–238.
   Google Scholar
• Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006;10:222–227.
   PubMed Web of Science ®Google Scholar
• Davenport A, Mehta S. The acute dialysis quality initiative, Part VI: Access and anticoagulation in CRRT. Adv Ren Replace Ther. 2002;9:273–281.
   Google Scholar
• Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int. 1990;38:976–981.
   PubMed Web of Science ®Google Scholar
• Opal S. Therapeutic rationale for antithrombin III in sepsis. Crit Care Med. 2000;28:S34–S37.
   PubMed Web of Science ®Google Scholar
• Baudo F, Caimi TM, de Cataldo F, Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or post surgical complications: A controlled double-blind, randomized, multicenter study. Intensive Care Med. 1998;24:336–342.
   PubMed Web of Science ®Google Scholar
• Singer M, McNally T, Screaton G, Mackie I, Machin S, Cohen S. Heparin clearance during continuous veno-venous hemofiltration. Intensive Care Med. 1994;20:212–215.
   Google Scholar
• Warkentin TE, Levine MN, Hirsh J, Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330–1335.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Siragusa S, Girolami B, Fabris F, BELZONI Investigators Group. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: A prospective cohort study. Blood. 2005;106:3049–3054.
   PubMed Web of Science ®Google Scholar
• Verma A, Levine M, Shalansky S, Carter C, Kelton JG. Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy. 2003;23:745–753.
   PubMedGoogle Scholar
• Clark NP. Low-molecular weight heparin use in the obese, elderly, and in renal insufficiency. Thromb Res. 2008;123:S58–S61.
   Google Scholar
• Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: Low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144:673–684
   PubMed Web of Science ®Google Scholar
• Reeves J, Cumming A, Gallagher L, Santamaria J. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med. 1999;27:2224–2228.
   PubMed Web of Science ®Google Scholar
• Harenberg J, Haaf B, Dempfle C, Stehle G, Heene D. Monitoring of heparins in hemodialysis using an anti-factor-Xa-specific whole-blood clotting assay. Nephrol Dial Transplant. 1995;10:217–222.
   Google Scholar
• Hofbauer R, Moser D, Frass M, Effect of anticoagulation on blood membrane interactions during hemodialysis. Kidney Int. 1999;56:1578–1583.
   PubMed Web of Science ®Google Scholar
• De Pont AC, Oudemans-van Straaten HM, Roozendaal K, Zandstra DF. Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: A double-blind, randomized, crossover study. Crit Care Med. 2000;28:421–425.
   PubMedGoogle Scholar
• Jeffrey RF, Khan AA, Douglas JT, Will EJ, Davison AM. Anticoagulation with low molecular weight heparin (Fragmin) during continuous hemodialysis in the intensive care unit. Artif Organs. 1993;17:717–720.
   Google Scholar
• Joannidis M, Kountchev J, Rauchenzauner M, Enoxaparin vs. unfractioned heparin for anticoagulation during continuous veno-venous hemofiltration: A randomized controlled crossover study. Intensive Care Med. 2007;33:1571–1579.
   PubMed Web of Science ®Google Scholar
• Pautas E, Siguret V, d'Urso M, Monitoring of tinzaparin in a ten day treatment dose in elderly patients. Rev Med Interne. 2001;22:120–126.
   PubMed Web of Science ®Google Scholar
• Pautas E, Gouin I, Bellot O, Andreux JP, Siguret V. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf. 2002;25:725–733.
   PubMed Web of Science ®Google Scholar
• Quiles J, Avanzas P, Bueno H. Fatal retroperitoneal hemorrhage associated with enoxaparin and impaired renal function. Int J Cardiol. 2005;98:523–524.
   Google Scholar
• Gerlach A, Pinkworth K, Seth S, Tanna S, Barnes J. Enoxaparin and bleeding complications: A review in patients with and without renal insufficiency. Pharmacotherapy. 2000;20:771–775.
   PubMed Web of Science ®Google Scholar
• Krishnan V, Murray P. Pharmacologic issues in the critically ill. Clin Chest Med. 2003;24:671–688.
   PubMed Web of Science ®Google Scholar
• Thong C, Kam P. Heparin-induced thrombocytopenia. Curr Anaesth Crit Care. 2005;16:143–150.
   Google Scholar
• Sagedal S, Hartmann A, Sundstrom K, Bjornsen S, Fauchald P, Brosstad F. A single dose of dalteparin effectively prevents clotting during hemodialysis. Nephrol Dial Transplant. 1999;14:1943–1947.
   PubMed Web of Science ®Google Scholar